Regulatory FDA’s ODAC delivers one loss, one win for AstraZeneca PharmaphorumThe FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.OncologyRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaphorum The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitationNext: Amgen positions MariTide as potential ‘best monthly’ obesity drug Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
